On December 8th, Shanghai, Xinhua Finance and Economics reported that Sanofi's investor research and development day was recently held. Sanofi announced 12 new molecular entities with the potential for "heavyweight products", many of which have entered the later stage of research and development. Meanwhile, the company announced that newly launched innovative drugs are expected to contribute over 10 billion euros in annual sales by 2030.
The company expects the star drug Dabitol& Reg; We will continue to maintain strong performance and achieve a double-digit compound annual net sales growth rate from 2023 to 2030; In terms of vaccines, Sanofi expects to achieve annual sales of over 10 billion euros by 2030, with recently launched Beyfortus& Reg; It will also become one of the driving forces.
According to estimates, the number of Phase III clinical trials for Sanofi is expected to increase by 50% between 2023 and 2025, reaching the highest number of pipelines in history. In addition, it is expected that 25 mid to late stage clinical trial results will be released and up to 19 new products or indications will be submitted for market application in the next two years.
The R&D leader of Sanofi stated that the company's strategic decision to focus on R&D innovation will fully unleash the maximum potential of its product pipeline. With these innovative pipelines, Sanofi will further consolidate its position in the fields of immunity and neuroinflammation.
Paul Hudson, CEO of Sanofi, said, "The recent continuous launch of several innovative drugs by Sanofi reflects our determination to provide breakthrough therapies. We are confident in our current product portfolio and future pipeline, and believe that this will provide sustainable growth momentum for the company until 2030 and even longer."